Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Oncorus Inc. is raising $79,551,797.00 in a new round of investment. Sources indicate as part of senior management President and Chief Executive Officer, Ted Ashburn played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Oncorus Inc.

Oncorus is a pre-clinical stage biotechnology company developing innovative and impactful, next-generation oncolytic HSV products with unprecedented potential to recruit all arms of immune system to treat solid tumors. The Oncorus family is dedicated to bringing hope and impactful therapies to cancer patients everywhere. As part of our commitment, we have taken a pledge to donate a portion of product sales to fund promising cancer research and to support cancer care in the developing world.

To learn more about Oncorus Inc., visit http://oncorus.com/

Contact:
Ted Ashburn, President and Chief Executive Officer
857-320-6400
https://www.linkedin.com/in/ted-t-ashburn-md-phd-b041631/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved